Tiziana Life Sciences, Ltd. (TLSA), a biotechnology firm, announced the immediate appointment of Ivor Elrifi as its new Chief Executive Officer (CEO) on Monday. Elrifi succeeds Gabriele Cerrone, who will continue his tenure as Executive Chairman of the board after serving as interim CEO.
Elrifi brings with him a wealth of experience, having served as the global head of the Patent Group at Cooley since 2014, and prior to that, leading the global Patents division at Mintz Levin from 1999 to 2014.
Throughout his career, Elrifi has provided counsel to organizations across a range of critical sectors, including pharmaceuticals, biotechnology, life sciences, and medical devices. His clients have spanned research institutions, universities, hospitals, and government bodies worldwide, particularly in the United States and Europe.
Elrifi's expertise extends to advising clients on strategic transactions, including investments, business development, and mergers and acquisitions. Notably, he has been involved in acquisition transactions with major corporations such as Novartis, Eli Lilly, Biogen, and Astellas.
